Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints and data collection requirements for clinical studies
Apostolos Tzikas1*, MD, PhD; David R. Holmes Jr2, MD; Sameer Gafoor3, MD; Carlos E. Ruiz4, MD, PhD; Carina Blomström-Lundqvist5, MD, PhD; Hans-Christoph Diener6, MD; Riccardo Cappato7, MD; Saibal Kar8, MD; Randal J. Lee9, MD, PhD; Robert A. Byrne10, MB, BCh, PhD; Reda Ibrahim11, MD; Dhanunjaya Lakkireddy12, MD; Osama I. Soliman13, MD, PhD; Michael Näbauer14, MD; Steffen Schneider15, PhD; Johannes Brachman16, MD; Jeffrey L. Saver17, MD; Klaus Tiemann18, MD;
1. AHEPA University Hospital, Thessaloniki, Greece; 2. Mayo Clinic, Rochester, MN, USA; 3. CardioVascular Center Frankfurt, Frankfurt, Germany; 4. Hackensack UMC Heart and Vascular Hospital and The Joseph M. Sanzari Children’s Hospital, Hackensack, NJ, US
The increasing interest in left atrial appendage occlusion (LAAO) for ischaemic stroke prevention in atrial fibrillation (AF) fuels the need for more clinical data on the safety and effectiveness of this therapy. Besides an a